目錄 | | 頁次 | | --- | --- | | 公司資料 | 2 | | 財務摘要 | 4 | | 董事長致辭 | 5 | | 管理層討論及分析 | 6 | | 董事及高級管理層履歷 | 30 | | 董事會報告 | 35 | | 企業管治報告 | 64 | | 獨立核數師報告 | 78 | | 綜合損益表 | 83 | | 綜合損益及其他全面收益表 | 84 | | 綜合財務狀況表 | 85 | | 綜合權益變動表 | 87 | | 綜合現金流量表 | 89 | | 財務報表附註 | 90 | | 財務概要 | 159 | | 釋義 | 160 | 公司資料 董事會 執行董事 李靜女士 （董事會主席） Silvio Rudolf SCHAFFNER先生 （自2024年6月12日起調任為非執行董事） 非執行董事 Acotec Scientific Holdings Limited ( 於開曼群島註冊成立的有限公司 ) 股份代號 : 6669 2024 年度報告 Silvio Rudolf SCHAFFNER先生 （自2024年6月12日起調任為非執行董事） Arthur Crosswell BUTCH ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6669） 截至2024年12月31日止年度之年度業績公告 年度業績摘要 財務概要 | | 截至2024年 | 截至2023年 | | | --- | --- | --- | --- | | | 12月31日 | 12月31日 | | | | 止年度 | 止年度 | 按年變動 | | | 人民幣千元 | 人民幣千元 | | | 收益 | 533,988 | 473,848 | 12.7% | | 毛利 | 402,722 | 377,415 | 6.7% | | 除稅前溢利 | 52,601 | 14,452 | 264.0% | | 年內溢利 | 52,280 | 14,487 | 260.9% | 業務摘要 於2024年，我們持續推動技術及流程的創新及迭代， ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 292.3 million, representing a 20.3% increase compared to RMB 243.1 million for the same period in 2023[5]. - Gross profit for the same period was RMB 217.2 million, an increase of 11.3% from RMB 195.1 million year-on-year[5]. - Profit before tax surged to RMB 39.9 million, marking a significant increase of 78.7% from RMB 22.4 million in the previous year[5]. - The company reported a total comprehensive income of RMB 40,329,000 for the period, compared to RMB 23,890,000 in the previous year[89]. - Net profit for the period was RMB 39,957,000, a significant increase of 78.8% from RMB 22,369,000 in the previous year[89]. - Basic and diluted earnings per share for the period were both RMB 0.13, compared to RMB 0.07 in the same period last year[88]. - The company generated approximately RMB 174.6 million from core product sales, reflecting a year-on-year increase of about 14.2%[36]. - Revenue from diversified products, including peripheral suction systems and radiofrequency ablation systems, contributed approximately RMB 117.7 million, accounting for about 40.3% of total revenue[8]. Product Development and Innovation - The company has established approximately 30 product pipelines across vascular surgery, cardiology, nephrology, and neurology, focusing on minimally invasive interventional solutions[6]. - The product pipeline includes approximately 30 diverse products across vascular surgery, cardiology, nephrology, and neurology, demonstrating strong market potential and execution capabilities[9]. - The company registered six new patents and submitted six additional patent applications during the reporting period[7]. - AcoArt Litos® received FDA IDE approval in November 2023, marking a significant milestone for entry into the U.S. market, with clinical trials currently being prepared[9]. - Three products received approval from the National Medical Products Administration during the reporting period, including Peridge®, Wingyan®, and Vericor-RS®[12]. - The company is actively cultivating the market for new products to provide innovative treatment solutions for clinical patients[10]. - The company has a strong internal R&D team with 63 registered patents and 38 pending patent applications as of June 30, 2024[34]. Market Expansion and Strategic Partnerships - The company has expanded its international presence, preparing to enter markets in Chile, Austria, Finland, Sweden, the Netherlands, and the UK[8]. - A strategic cooperation agreement was signed with Boston Scientific Group plc to enhance product commercialization and development over the next three years[8]. - A framework agreement with BSG was established on July 20, 2023, to enhance global market sales opportunities for the company's products[40]. - The company aims to become a global leader in providing comprehensive interventional solutions for vascular diseases[39]. Financial Position and Resources - As of June 30, 2024, the total available financial resources amounted to approximately RMB 930.4 million, an increase of about 5.8% from RMB 879.4 million as of December 31, 2023[54]. - The total borrowings as of June 30, 2024, were RMB 55.0 million, up from RMB 10.0 million as of December 31, 2023, resulting in a capital debt ratio increase from approximately 24.3% to 27.8%[55]. - The net current assets as of June 30, 2024, were approximately RMB 1,113.4 million, an increase of about 1.7% from RMB 1,094.9 million as of December 31, 2023[56]. - The company plans to continue expanding in both domestic and global markets and will support capital expenditures through various financing channels, including internal funds and bank loans[62]. Operational Efficiency and Cost Management - The cost of sales for the six months ended June 30, 2024, was approximately RMB 75.1 million, a significant increase of about 56.7% from RMB 47.9 million in the previous year[43]. - Gross profit increased by approximately 11.3% to about RMB 217.2 million, but the gross margin decreased from 80.3% to 74.3% due to lower margins on certain products[44]. - Research and development costs rose by approximately 11.8% to RMB 100.5 million, driven by an increase in R&D personnel and ongoing project investments[48]. - Administrative expenses decreased by approximately 11.8% to RMB 33.8 million for the six months ended June 30, 2024, from RMB 38.3 million for the same period in 2023[50]. Shareholder Information and Corporate Governance - The company does not recommend an interim dividend for the six months ending June 30, 2024[66]. - The company intends to retain future profits for business operations and expansion, with no current plans for dividend distribution[67]. - As of June 30, 2024, Boston Scientific Group plc (BSG) holds 203,702,962 shares, representing 65% of the company's equity[76]. - The company has adopted a corporate governance code and has complied with all applicable provisions, except for the separation of the roles of Chairman and CEO[67].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告載有涉及風險及不明確因素的前瞻性陳述。除過往事實陳述以外的所有陳述均為前瞻性 陳述。本公告所載之該等聲明不應被視為董事會或本公司表示將實現該等計劃及目標。該等陳 述涉及已知及未知的風險、不明確及其他因素，當中部分並非本公司所能控制，且可導致實際 業績、表現或成果與該等前瞻性陳述所明示或暗示者存在重大差異。 閣下不應依賴前瞻性陳 述作為未來事件的預測。本公司概不承擔任何更新或修訂任何前瞻性陳述的責任，無論是否由 於新資料、未來事件或其他因素所致。 Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6669） 截至2024年6月30日止六個月之中期業績公告 | --- | --- | --- | --- | |------------|-------------------------|----------- ...

Financial Performance - Total revenue for the year ended December 31, 2023, reached approximately RMB 473.8 million, a year-on-year increase of 19.8%[23] - Gross profit for the same period was approximately RMB 377.4 million, reflecting a year-on-year growth of 12.2%[23] - The company reported a significant decrease in profit before tax, down 79.4% to RMB 14.5 million from RMB 70.3 million in the previous year[23] - Adjusted net profit for the year was RMB 42.4 million, representing a year-on-year increase of 22.1%[23] - The company's revenue for the year ended December 31, 2023, was approximately RMB 473.8 million, an increase of about 19.8% compared to RMB 395.5 million for the year ended December 31, 2022[58] - Sales of core products, particularly AcoArt Tulip® and Litos®, contributed significantly to revenue growth, with core product sales reaching RMB 323.5 million, accounting for 68.3% of total revenue[59] - Revenue from venous intervention, vascular access, and other products increased by approximately 70.3%, rising from 22.3% of total revenue in 2022 to 31.7% in 2023[58] Product Development and Innovation - The company launched four new products in 2023, including the RT-Zero® coronary CTO balloon and AcoStream® second-generation peripheral thrombectomy system[27] - AcoArt Litos®, the world's first clinically validated below-the-knee drug-coated balloon, received FDA investigational device exemption (IDE) approval for clinical studies in the U.S.[27] - The company registered 19 new patents and submitted 26 new patent applications during the reporting period[30] - The company’s product pipeline includes over 30 products across various medical fields, with significant advancements in research and clinical trials in 2023[32] - The company received FDA IDE approval for clinical research of the BTK DCB in the United States, marking a significant milestone in its product development[32] - The company is advancing production development at a rapid pace, with significant progress in its product pipeline[35] - The company plans to commercialize 15 products by 2026, with several receiving regulatory approvals, including CE and NMPA certifications[35] Regulatory Approvals and Market Expansion - Four products received approval from the National Medical Products Administration during the reporting period, including two upgraded versions: AcoStream® II and ACOART AVENS®[34] - The coronary CTO recanalization balloon (RT-Zero®) and the coronary CTO antegrade microcatheter (Vericor-14®) further expand the company's product portfolio in the cardiology field[34] - The company is expanding the indications for AcoArt Orchid® & Dhalia® to include treatment for vertebral artery atherosclerotic stenosis, with expected regulatory approval in 2024[38] - The company anticipates obtaining regulatory approval for the peripheral scoring balloon in 2024, having submitted the product registration in 2023[45] - The company expects to obtain regulatory approval for the coronary rapamycin DCB in 2024, following the completion of clinical trials[47] Strategic Partnerships and Collaborations - The company established a strategic partnership with Boston Scientific, outlining collaboration in product commercialization, manufacturing services, and product development over the next three years[31] - A framework agreement was signed with BSG on July 20, 2023, to regulate ongoing related party transactions and facilitate global market sales of the company's products[56] - The cooperation agreement allows BSG to sell its products through the company in the Greater China region, and vice versa[128] Research and Development - The company has a strong internal R&D team with 66 registered patents and 30 pending applications as of December 31, 2023[51] - Research and development costs for the year ended December 31, 2023, were approximately RMB 1,901 million, a 3.4% increase from RMB 1,838 million for the year ended December 31, 2022, mainly due to an increase in the number of R&D personnel[63] - The company aims to enhance its R&D capabilities through increased investment in technological innovation to maintain its leading position in the DCB market[57] Financial Position and Liabilities - Non-current assets increased by 159.5% to RMB 399.9 million as of December 31, 2023, compared to RMB 154.1 million in 2022[25] - Total assets grew by 14.2% to RMB 1,611.1 million in 2023, up from RMB 1,410.5 million in 2022[25] - Total liabilities increased by 133.9% to RMB 314.5 million in 2023, compared to RMB 134.5 million in 2022[25] - The company's capital debt ratio increased from approximately 10.5% as of December 31, 2022, to approximately 24.3% as of December 31, 2023, mainly due to an increase in lease liabilities[72] Corporate Governance and Management - The board of directors consists of seven members, including two executive directors and three independent non-executive directors, ensuring a balanced governance structure[186] - The company has established three committees: audit committee, remuneration committee, and nomination committee, each with defined responsibilities[197] - The audit committee confirmed that the annual performance for the year ending December 31, 2022, complied with relevant accounting standards and regulations[199] Market Strategy and Sales - The company employs a strategic marketing model, leveraging relationships with hospitals and a KOL network to promote products in China[53] - The company is focusing on expanding its core products across three therapeutic areas, indicating a strategic approach to market growth[36] - The company aims to diversify its revenue sources through accelerated international business development, enhancing its ability to respond to market changes[78] Employee and Workforce Development - As of December 31, 2023, the company employed a total of 638 staff, with the R&D team growing to 127 members, enhancing its talent pool[33] - The company has implemented various internal occupational health and safety procedures to maintain a safe working environment[103] Shareholder and Equity Information - The total reserves available for distribution to equity shareholders as of December 31, 2023, amounted to RMB 1,341,822,000, a decrease from RMB 1,357,317,000 in 2022[107] - The company has confirmed the independence of all independent non-executive directors as of the report date[114] - The board does not recommend the distribution of a final dividend for the year ending December 31, 2023[80] Environmental and Social Responsibility - The company emphasizes its commitment to sustainable development and environmental responsibility in its operations[101] - The total amount of donations made by the group for the year ended December 31, 2023, was approximately RMB 1.83 million[177]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 * 經調整項目詳情參閱本年度業績公告內的非國際財務報告準則計量。 先端达 Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6669） 截至2023年12月31日止年度之年度業績公告 | --- | --- | --- | --- | |-------------------------------------------|----------------------------------------------|--------------------------------------------|---------------| | | | | | | 年度業績摘要 | | | | | 財務概要 | 截至 2023 年 12 月 31 日 止年度 人民幣千元 | 截至 2022 年 12 月 31 日 ...

AGOTEC Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 股份代號 : 6669 （於開曼群 島 註 冊 成 立 的 有 限 公 司 ） 2023 中期報告 目錄 綜合權益變動表 35 公司資料2 財務概要4 管理層討論及分析5 其他資料 25 獨立核數師審閱報告 30 綜合損益表 31 綜合損益及其他全面收益表 32 綜合財務狀況表 33 簡明綜合現金流量表 37 未經審核中期財務報告附註 38 釋義 56 公司資料 合規顧問 | --- | --- | |------------------------------------------------------|---------------------------------------------------------| | 董事會 | 主要往來銀行 | | 執行董事 | 中信銀行（北京門頭溝支行） | | | 中國 | | 李靜女士 （董事會主席） Silvio Rudolf SCHAFFNER 先生 | 北京 門頭溝區石龍南路 1 號 | | 非執行董事 | 駿洋國際大廈 1 層 | | A ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Acotec Scientific Holdings Limited 先瑞達醫療科技控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6669） 截 至2022年12月31日止年度年報的補充公告 茲提述先瑞達醫療科技控股有限公司（「本公司」）於2023年4月24日刊發的截至 2022年12月31日止年度的年度報告（「年 報」）。除 本 公 告 另 有 界 定 者 外，本 公 告 所 使 用 詞 彙 與 年 報 中 所 界 定 者 具 有 相 同 涵 義。除 本 公 司 於 年 報 中 所 作 披 露 外，本 公 司 謹 此 提 供 以 下 有 關 本 公 司 受 限 制 股 份 單 位 計 劃 及 股 份 獎 勵 計 劃 的 資 料。 受限制股份單位計劃 下表載列於報告期內根據受限制股份單位計劃授予承授人的 ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 243,063 thousand, representing a 38.6% increase from RMB 175,322 thousand in the same period of 2022[2] - Gross profit for the same period was RMB 195,116 thousand, up 34.8% from RMB 144,770 thousand year-on-year[2] - Profit before tax decreased by 28.6% to RMB 22,351 thousand compared to RMB 31,290 thousand in the previous year[2] - Net profit for the period was RMB 22,369 thousand, down 28.1% from RMB 31,096 thousand in the prior year[2] - Adjusted net profit increased by 83.8% to RMB 35,715 thousand from RMB 19,430 thousand year-on-year[2] - The company reported a total comprehensive income of RMB 23,890 thousand for the period, compared to RMB 31,189 thousand in the previous year[6] - The company reported external customer revenue from mainland China of RMB 236,974,000, a 38.5% increase from RMB 171,048,000 in the prior year[20] - The company reported a net loss of RMB 8,086,000 in foreign exchange gains/losses for the six months ended June 30, 2023, compared to a gain of RMB 15,152,000 in the same period of 2022[24] - The total finance costs for the six months ended June 30, 2023, amounted to RMB 4,357,000, significantly higher than RMB 866,000 in the previous year[25] - The company recorded a net other loss of approximately RMB 7.1 million for the six months ended June 30, 2023, compared to a net other income of RMB 15.1 million for the same period in 2022, primarily due to foreign exchange losses[80] Assets and Liabilities - Non-current assets increased significantly, with property, plant, and equipment valued at RMB 87,100 thousand, up from RMB 68,928 thousand[7] - Current assets totaled RMB 1,229,104 thousand, slightly down from RMB 1,256,438 thousand at the end of 2022[7] - Total equity attributable to shareholders increased to RMB 1,305,239 thousand from RMB 1,276,089 thousand[10] - The total non-current assets as of June 30, 2023, were RMB 339,840,000, compared to RMB 129,769,000 as of December 31, 2022[18] - Trade receivables, net of loss provisions, stood at RMB 116,507,000 as of June 30, 2023, compared to RMB 131,909,000 at the end of 2022[34] - The total amount of trade and other payables decreased to RMB 57.111 million from RMB 74.090 million as of December 31, 2022[35] - Cash and cash equivalents as of June 30, 2023, were approximately RMB 947.8 million, a decrease of about 3.9% from RMB 986.5 million as of December 31, 2022[92] - The net current assets of the group were approximately RMB 1,141.0 million as of June 30, 2023, a decrease of about 1.4% from RMB 1,157.8 million as of December 31, 2022[94] - The capital-to-debt ratio increased from approximately 10.5% as of December 31, 2022, to about 22.9% as of June 30, 2023, primarily due to an increase in lease liabilities[93] Research and Development - Research and development expenses rose to RMB 89,877 thousand, compared to RMB 77,070 thousand in the same period last year[4] - The company operates primarily in the blood-related disease treatment solutions sector, focusing on research and development[15] - The company is actively advancing its product pipeline, focusing on arterial diseases, venous diseases, and vascular tumors[43] - R&D expenses for the six months ended June 30, 2023, were approximately RMB 89.9 million, an increase of about 16.6% compared to RMB 77.1 million for the same period in 2022[82] - Employee benefits accounted for 44.6% of R&D expenses in 2023, up from 37.5% in 2022, reflecting increased personnel costs[83] - The company aims to enhance its R&D capabilities by increasing investment in technological innovation to strengthen its competitive position in the DCB market[73] Product Development and Approvals - In the first half of 2023, the company received approvals for four products from the National Medical Products Administration, enhancing its market presence[45] - The second-generation peripheral suction system (AcoStream®) was launched, offering improved therapeutic effects and ease of use compared to the first generation[45] - The company obtained approvals for two cardiac products: the coronary CTO recanalization balloon (RT-Zero®) and the coronary CTO retrograde microcatheter (Vericor-14®)[45] - The company’s paclitaxel-coated high-pressure balloon (ACOART AVENS®) received approval, strengthening its influence in the renal field[45] - The company has a total of 14 commercialized products and 18 products in development across three therapeutic areas[46] - The company is expanding the indications for AcoArt Orchid® & Dhalia® in treating vertebral artery atherosclerotic stenosis, with RCT enrollment completed in 2022 and expected approval in 2024[49] Market and Sales Performance - Revenue from core products, specifically drug-coated balloons (DCB), was RMB 152,874,000, up from RMB 142,898,000, indicating a growth of 7.4%[16] - Revenue from vascular intervention and access products surged to RMB 88,939,000, a significant increase from RMB 30,575,000, reflecting a growth of 190.5%[16] - Other commercialized products, including AcoStream® and AcoArt Cedar®, generated approximately RMB 88.9 million in revenue, accounting for about 36.6% of total revenue during the reporting period[40] - Sales from core products AcoArt Orchid® & Dhalia® and AcoArt Tulip® & Litos® generated approximately RMB 152.9 million, reflecting a year-on-year increase of about 7.0%[71] - Sales from venous intervention and vascular access products amounted to approximately RMB 88.9 million, with a significant year-on-year increase of about 190.9%[71] Corporate Governance and Strategy - The company maintains a high level of corporate governance to protect shareholder interests and enhance corporate value[105] - The board believes that the current structure, with the same individual serving as both Chair and CEO, ensures effective leadership and strategic planning[105] - The company plans to retain all future profits for business operations and expansion, with no current dividend policy in place[105] - The company is exploring strategic acquisitions to bolster its market position[112] - The company has strengthened its talent pool in hardware design, engineering, and materials science during the reporting period[70] Future Outlook - Future outlook includes expansion in the market and potential new product launches[112] - The company has set performance guidance for the upcoming quarters, anticipating growth in revenue[112] - The company expects to generate more cash from operating activities through increased sales of existing commercialized products and the launch of new products[92] - The company plans to expand its product offerings in five therapeutic areas, including vascular surgery, cardiology, nephrology, neurology, and urology, by increasing the indications for DCB products[73]

Financial Performance - For the fiscal year ending December 31, 2022, the total revenue was approximately RMB 395.5 million, representing a year-on-year increase of 30.2%[6] - Gross profit for the same period was approximately RMB 336.4 million, with a year-on-year growth of 26.5%[6] - The net profit for the year was approximately RMB 70.1 million, a significant recovery from a loss of RMB 79.1 million in the previous year[6] - The company achieved a revenue of approximately RMB 395.5 million in 2022, representing a year-on-year increase of about 30.2%[12] - Revenue from AcoArt Orchid® & Dhalia® sales in China and overseas was approximately RMB 270.8 million, representing a decrease of about 1.5% year-on-year[23] - Revenue from core products and venous intervention products was approximately RMB 307.3 million and RMB 86.0 million, representing increases of approximately 2.7% and 1,763.8%, respectively[40] - The company's revenue for the year ended December 31, 2022, was approximately RMB 395.5 million, an increase of about 30.2% compared to RMB 303.8 million for the year ended December 31, 2021[44] Product Development and Innovation - The company received approval for five new products and one DCB product indication expansion from the National Medical Products Administration in 2022[8] - The company has submitted 18 patent applications during the reporting period, with 4 applications already approved[12] - The company has launched five new products and received NMPA registration approvals for these products during the reporting period[16] - The company has expanded its product coverage to include cardiology, nephrology, and neurology, in addition to peripheral vascular diseases[12] - The company is focused on accelerating its internationalization process to diversify its revenue sources and respond flexibly to market changes[12] - The company is expanding the indications for AcoArt Orchid® & Dhalia® in treating vascular-related erectile dysfunction[25] - The company is expanding its core products AcoArt Orchid® & Dhalia® and AcoArt Tulip® & Litos® for the treatment of vascular erectile dysfunction, with expected regulatory approval in 2025[38] Financial Position and Assets - Total assets as of December 31, 2022, were RMB 1.41 billion, a 7.9% increase from the previous year[7] - Total liabilities increased by 34.2% to RMB 134.5 million, with current liabilities rising by 12.0%[7] - The total equity amounted to RMB 1.28 billion, reflecting a 5.7% increase year-on-year[7] - Cash and cash equivalents as of December 31, 2022, were approximately RMB 986.5 million, a decrease of about 13.3% from RMB 1,137.2 million in 2021, attributed to increased operating and investment expenditures[61] - The company's total borrowings were zero as of December 31, 2022, down from approximately RMB 6.0 million in the previous year[62] - The debt-to-equity ratio increased from approximately 8.3% in 2021 to about 10.5% in 2022[62] Research and Development - The company’s R&D team has grown to 118 members, enhancing its talent pool in various technical fields[14] - Research and development expenses for the year ended December 31, 2022, were approximately RMB 183.8 million, an increase of about 30.1% from RMB 141.3 million in 2021, driven by the acquisition of R&D centers and increased investment in ongoing projects[51] - The company is committed to clinical research and development to advance its product offerings and improve patient outcomes[90] Market Expansion and Strategy - The company aims to become a global leader in vascular disease intervention solutions, planning to expand DCB product indications across five treatment areas[43] - The company plans to enhance sales efforts for AcoArt Orchid® & Dhalia® and improve awareness of DCB products among patients in China[43] - The company intends to accelerate clinical development and commercialization of late-stage products while expanding sales penetration globally, particularly in Europe and the United States[43] - The company plans to continue expanding in both domestic and global markets and will support capital expenditures through various financing channels, including internal funds and bank loans[66] Governance and Management - The board of directors consists of seven members, including two executive directors and three independent non-executive directors, ensuring a balanced governance structure[157] - The company emphasizes high corporate governance standards and has adopted the principles and code provisions of the corporate governance code as per the listing rules[155] - The company has established three committees: the audit committee, the remuneration committee, and the nomination committee, each with defined responsibilities and reporting to the board[167] - The company has implemented various occupational health and safety procedures to maintain a safe working environment, with no significant claims or disputes reported[98] Risks and Compliance - The company faced significant risks including the lengthy and costly clinical product development process, which may lead to additional costs or delays[95] - The company has established various risk management procedures and internal control processes across major business and functional departments, including sales, procurement, and financial management[178] - The company has ensured that all directors confirmed compliance with the code of conduct regarding securities trading during the reporting period[180] Shareholder Relations - The company emphasizes the importance of effective communication with shareholders to enhance investor relations and ensure transparency in financial disclosures[184] - The company has set up various communication channels to respond to stakeholder inquiries effectively[193] - The board of directors will regularly review the company's status and consider adopting a dividend policy at an appropriate time[194]